Table 1 Correlation of IL-32 expression level with clinicopathological features in ESCC patients
Variables | All cases (N) | IL-32 expression level (IHC-score) | P valuea, b | |
|---|---|---|---|---|
Low, N (%) | High, N (%) | |||
Age (year) | ||||
 < 57 | 15 | 9 (16.1) | 6 (10.7) | 0.905 |
 >=57 | 41 | 22 (39.3) | 19 (33.9) |  |
Gender | ||||
 Male | 41 | 24 (42.9) | 17 (30.4) | 0.626 |
 Female | 15 | 7 (12.5) | 8 (14.3) |  |
Tumor location | ||||
 Upper | 9 | 8 (14.3) | 1 (1.8) | 0.087 |
 Middle | 33 | 16 (28.6) | 17 (30.4) |  |
 Lower | 14 | 7 (12.5) | 7 (12.5) |  |
Tumor differentiation | ||||
 Well | 10 | 8 (14.3) | 2 (3.6) | 0.159 |
 Moderate | 33 | 15 (26.8) | 18 (32.1) |  |
 Poor | 13 | 7 (12.5) | 6 (10.7) |  |
Pathological stage | ||||
 IA-IB | 9 | 6 (10.7) | 3 (5.4) | 0.304 |
 IIA-IIB | 22 | 14 (25) | 8 (14.3) |  |
 IIIA-IIIC | 25 | 11 (19.6) | 14 (25) |  |
Tumor stage | ||||
 T1-T2 | 24 | 13 (23.2) | 11 (19.6) | 0.265 |
 T3-T4 | 32 | 18 (32.1) | 14 (25) |  |
Nodal stage | ||||
 N0 | 27 | 18 (32.1) | 9 (16.1) | 0.025* |
 N1 | 21 | 12 (21.4) | 9 (16.1) |  |
 N2-N3 | 8 | 1 (1.8) | 7 (12.5) |  |